Akari Therapeutics, Plc
NCM: AKTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Akari Therapeutics, Plc's price action across multiple timeframes using regression channels and statistical scoring.
Get AKTX Z-Score →About Akari Therapeutics, Plc
Healthcare
Biotechnology
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Akari Therapeutics, Plc demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -68.4%, which indicates that capital utilization is currently under pressure.
At a current price of $3.83, AKTX currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $3.25 - $63.20).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$4.38M
Trailing P/E
inf
Forward P/E
-0.27
Beta (5Y)
0.54
52W High
$63.20
52W Low
$3.25
Avg Volume
16K
Day High
Day Low